Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Harrison

Showing results (121-130 of 153) with videos related to

Pageof 16
Sort By:
Cell Death and Differentiation|January 29, 2020
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cellsCharis E Teh, Jia-Nan Gong, David Segal, et al.
Expert Review of Hematology|September 5, 2023
Modifiable lifestyle risk factors and survival after diagnosis with multiple myelomaSimon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Cancer Discovery|May 17, 2019
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation StudyAmit Khot, Natalie Brajanovski, Donald P Cameron, et al.
Ejhaem|July 18, 2022
Alcohol and tobacco use and risk of multiple myeloma: A case-control studySimon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Haematologica|May 20, 2021
Myeloma natural killer cells are exhausted and have impaired regulation of activationCriselle D'Souza, Simon P Keam, Han Xian Aw Yeang, et al.
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Blood|July 11, 2025
Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsRaymond K H Yip, Jeremy Er, Lei Qin, et al.
Pageof 16

Showing results (121-130 of 153) with videos related to

Sort By:
Pageof 16
Cell Death and Differentiation|January 29, 2020
Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cellsCharis E Teh, Jia-Nan Gong, David Segal, et al.
Expert Review of Hematology|September 5, 2023
Modifiable lifestyle risk factors and survival after diagnosis with multiple myelomaSimon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Cancer Discovery|May 17, 2019
First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation StudyAmit Khot, Natalie Brajanovski, Donald P Cameron, et al.
Ejhaem|July 18, 2022
Alcohol and tobacco use and risk of multiple myeloma: A case-control studySimon Cheah, Julie K Bassett, Fiona J Bruinsma, et al.
Haematologica|May 20, 2021
Myeloma natural killer cells are exhausted and have impaired regulation of activationCriselle D'Souza, Simon P Keam, Han Xian Aw Yeang, et al.
Blood|April 8, 2026
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myelomaHans C Lee, Wouter J Plattel, Simon J Harrison, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Blood|August 30, 2017
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MMPhilippe Moreau, Asher Chanan-Khan, Andrew W Roberts, et al.
Blood|July 11, 2025
Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsRaymond K H Yip, Jeremy Er, Lei Qin, et al.
Pageof 16